Preclinical studies nominate STING + venetoclax (± HMA) as a coherent strategy, with a 2025 phase I trial reporting a 35% CR rate in TP53-mutant AML with STING agonist + venetoclax + azacitidine (Singh et al., 2025). This evidence concerns the gene STING1 and acute myeloid leukemia.